不同用药方案治疗儿童哮喘的临床观察

Clinical observation of different medication in the treatment of childhood asthma

目的探讨不同用药方案治疗儿童哮喘的临床疗效。方法选择98例儿童哮喘患儿为研究对象,随机分为孟鲁司特钠组、布地奈德组、对照组,分别给予孟鲁司特钠每晚5mg顿服、布地奈德气雾剂200μg/次,1次/d及还尔金5g/次,2次/d口服,12周后观察三组哮喘控制情况及肺功能改善情况,并进行比较。结果孟鲁司特钠组及布地奈德组治疗后FEV1、PEF明显增加,差异有统计学意义(P<0.05)。孟鲁司特钠组及布地奈德组控制率与对照组比较均明显升高,差异有统计学意义(P<0.01),但孟鲁司特钠组与布地奈德组之间比较差异均无统计学意义(P>0.05)。结论口服孟鲁司特钠及低剂量吸入布地奈德对控制儿童哮喘及肺功能改善疗效确切。

Objective To explore clinical effects of different medication in the treatment of childhood as hma. Methods Selected 98 cases of children with asthma as research objects,randomly divide these children into montelukast sodium group,budesonide group and the control group,and give them montelukast sodium 5 mg per night,aerosol budesonide 200μg/time,1 time/d,and Elgin 5 g/time,2 times/d,orally. Twelve weeks later,observed and compared the control of asthma and improvement of lung function of three groups. Results After treatment,FEV1 and PEF of Montelukast sodium group and budesonide group were significantly increased,the difference was statistically significant（ P 0. 05）. Compared with control group,control rate of montelukast sodium group and budesonide group was significantly higher. The difference was statistically significant （ P 0. 01）. However,there was no statistically significant difference between montelukast sodium group and budes-onide group（ P 0. 05）. Conclusion Oral montelukast sodium and low-dose inhaled budesonide have a curative effect on controlling childhood asthma and improving lung function.